Gero

There has never been a better time to study aging. ⏱️ With advanced technology and #AI, we can predict individual well-being to fuel our science. By decomposing human health into clusters of disease and #aging, our process at Gero can be broken down to identify the steps needed to extend #longevity by linking core chronic disease biology to core aging mechanisms. Our Co-founder and CEO, Peter Fedichev, explained how our model operates at the 2026 J.P. Morgan HealthCare Conference. 👇

Understanding how to target #aging is not a one-size-fits-all approach. 🧬 Our Co-founder and CEO, Peter Fedichev, had the opportunity to join Eleanor Sheekey at Sheekey Science Solutions Limited to discuss why most products on the market target stress levels related to physical aging and homeostasis, but fail to target the physics needed to extend maximum lifespan. 📹 Watch to see how Gero is leading the future of #longevity: https://bit.ly/4d009z7 

"This week in Dubai" We’ll be hosting a private investor discussion on "why aging is becoming the next major drug category". The thesis is simple. Nature has already demonstrated that aging can be dramatically slowed. Some mammals (naked mole rats, some species of bats and whales) show little to no increase in mortality with age and live many times longer than closely related species. These are not curiosities — they are biological proof that the *rate of aging is adjustable*. What has been missing is a way to turn that insight into medicine. "Ozempic and Wegovy showed what happens when a fundamental biological process is reframed into a druggable target." Metabolism moved from lifestyle and wellness into one of the largest therapeutic categories in pharma. Aging is next. At Gero, we’ve followed the long path from first-principles science to drug discovery. Our work applies physics to model aging as a system-level process and to identify therapeutic interventions. This approach has since been formalized as Gerophysics, a new scientific field recognized by *Nature*. That foundation has translated into practice: publishing foundational scientific work, building AI-driven drug discovery platforms, demonstrating systemic rejuvenation in mammals, and establishing commercial partnerships with global pharmaceutical leaders including Pfizer and Roche. I’m looking forward to sharing what we’ve learned. "What we’ll discuss:" * What we now understand about aging — and what remains impossible (for now) * Why aging is moving beyond wellness into a druggable, multi-disease target * Which longevity approaches are unlikely to scale — and which can support real therapeutics * How physics-based models and AI make organism-level aging measurable and predictable * What this shift implies for pharma pipelines, investment strategy, and long-term value creation A central theme: "for the first time, currently living generations may realistically remain healthy long enough to experience a future that was previously out of reach" — a structural shift with implications far beyond healthcare. This is a "private session for investors and pharma executives" during World Health Expo week. If you’ll be in Dubai on "February 11" and this is relevant to your work, the link is in the comments. If you know someone for whom this discussion might be relevant, I’d appreciate you forwarding it to them.

This week, during J.P. Morgan Healthcare Conference week, we hosted a private, investor-focused session in San Francisco. Nearly 200 participants from investing, pharma, and biotech joined the discussion. Aging is emerging as the next true drug category — after GLP-1. The conversation examined why aging is moving from a wellness narrative into a druggable biological process; why many longevity approaches are unlikely to scale into real medicines; and how physics-based models and AI make organism-level aging predictable rather than anecdotal — enabling the design of transformative therapies targeting aging itself. Recent pharmaceutical collaborations, including work with Chugai (a member of the Roche Group), further validate this physics-based framework for aging, often referred to as Gerophysics. A highlight was a keynote by Peter Fedichev Peter Fedichev , outlining the shift from qualitative longevity claims to quantitative models that estimate real lifespan impact — and how this transition is already reshaping drug discovery and pharmaceutical strategy. What stood out most was the convergence: across investors, pharma leaders, and operators, there is growing alignment that aging is no longer just a background risk factor, but a controllable biological variable capable of anchoring an entirely new therapeutic class. Grateful to everyone who joined the conversation. — Gero Thank you, Alexey Strygin ! #JPM #JPMWeek #Aging #Biotechology #GLP1 #Ozempic

Gero is hiring! We're seeking a Statistical Geneticist, Computational Biologist, or Bioinformatics Scientist (expertise in deep learning applications in functional genomics is a plus). You'll advance our target discovery platform by working with large-scale population genetics datasets, multi-omics data, and AI models to identify therapeutic targets and speed up our drug discovery pipeline. Key Responsibilities: • Data management & preprocessing: Handle tabular data, genetics data (plink format), GWAS sumstats, molQTL. • Statistical Genetics: Conduct WGS/WES common and rare variant association studies, followed by post-GWAS integration using colocalization, mendelian randomization, and multi-omics (transcriptomics/proteomics) analysis. • Machine Learning: Implement classical ML and deep learning solutions for functional genomics. • Pipeline development & maintenance: Design, build, and maintain automated analysis pipelines for association studies, ensure code quality. What We Offer: • Competitive Compensation: Salary packages aligned with industry standards. • Remote-First: globally remote with flexible hours. • High-Trust Culture: minimal-bureaucracy environment with complete ownership. • Immediate Impact: Your contributions will drive our core therapeutic discovery engine from day one. • Publication Opportunities: Active support for publishing. Full job description attached. How to Apply: Interested candidates should submit a CV detailing their relevant experience, specific skills related to the requirements above, and suitability for the role to dreamjob+biojan26@gero.ai.

Our event is today at 6:30 PM in San Francisco. Last chance to register — link in the comments.

2025: FROM MODEL TO MONEY Leading industry media Longevity.Technology recently described 2025 as the year longevity crossed a critical threshold — from theory and models to capital, milestones, and execution. They highlighted how, in 2025, Gero’s AI-driven platform, built on its Gerophysics-based understanding of organism-level aging, moved beyond theoretical promise through a partnership with Chugai Pharmaceutical (Roche Group). The collaboration positioned Gero’s aging models not as an exploratory add-on, but as a core engine for drug discovery — explicitly linking Gerophysics-derived insights to target identification and therapeutic pipelines. It signals growing confidence that aging is not only scientifically tractable, but operationally actionable. 🔗 Full article in the first comment. 📍 January meetings • JPM Healthcare Conference (Jan 12–15) • Davos / WEF week (Jan 18–20) If you’ll be there and want to discuss Gerophysics, AI-driven target discovery, structure-free small-molecule design or longevity drug development, we’re happy to connect.

We’re thrilled to welcome Vern De Biasi as an Advisor to Gero. Vern brings over two decades of experience building partnerships and advancing innovation at the intersection of AI, data science, and drug discovery. Most recently, he served as VP of Business Development at BenevolentAI, where he led strategic collaborations to accelerate AI-driven therapeutics. Prior to that, Vern held senior leadership roles at Recursion, Cyclica (acquired by Recursion, Nasdaq: RXRX), and GSK, where he helped integrate digital, data, and emerging platform technologies across global R&D. At Gero, Vern will advise on global partnerships and ecosystem strategy as we continue to expand the reach of our AI platform for modeling disease mechanisms and developing next-generation therapeutics. Welcome, Vern! We’re excited to have you onboard as we advance the future of data-driven biology. #Gero #AI #DrugDiscovery #Biotech #Partnerships #Leadership

Gero at Fierce Biotech Week 2025! We were thrilled to join this year’s Fierce Biotech Week in Boston, where our Chief Business Officer, Alex Kadet, delivered a presentation on Gero’s partnership strategy and spoke on the panel, “From Fit to Function: Designing Partnerships That Drive Long-Term Value.” It was an inspiring week of discussions on how strategic collaborations and AI-driven innovation are reshaping the future of drug discovery and development. Thank you to the Fierce Biotech team for hosting such a dynamic event and to all the leaders driving meaningful progress across our industry. #FierceBiotechWeek #DrugDiscovery #AIinBiotech #Partnerships #BiotechInnovation #GeroAI

Excited to join Fierce Biotech Week for the panel “From Fit to Function: Designing Partnerships That Drive Long-Term Value.” Our Chief Business Officer Alex Kadet will speak alongside an incredible group of industry leaders shaping how biotech and pharma collaborations succeed over the long term: • Steven Damon, CEO, Micron Biomedical • Robyn Hunter, CFO, SOTIO Biotech • Alethia Young, CFO, Bicycle Therapeutics • Sameer Sabir, Co-Founder & CEO, Brixton Biosciences • Jeff Raphael, Managing Partner, OmniScope Partners 📅 Wednesday, Oct 8 | 4:30–5:15 PM 📍 Picasso 1 & 2, Fierce Biotech Week The discussion will explore how companies can design partnerships that thrive under scientific, strategic, and operational pressure — from governance and data sharing to milestone structuring and evolving priorities. Looking forward to a great conversation about building collaborations that truly deliver long-term value. #FierceBiotechWeek #Biotech #Pharma #Partnerships #BusinessDevelopment #AI #Longevity #Gero